Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10392438 Bispecific antibodies

Patent 10392438 was granted and assigned to Pfizer Limited on August, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Ruth E. Gimeno0

Kimberly A. Marquette0

Lioudmila Tchistiakova0

Nathan Higginson-Scott0

Eric M. Bennett0

Janet E. Paulsen0

Date of Patent

August 27, 2019

0

Patent Application Number

153098790

Date Filed

May 13, 2015

0

Patent Citations Received

US Patent 12060436 Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

0

US Patent 11066474 Anti-TrkB monoclonal antibodies and methods of use

US Patent 11286293 Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Patent Primary Examiner

0

Patent abstract

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10392438 Bispecific antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool